Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.685 -0.005 (-0.14%)
Streaming Delayed Price Updated: 10:15 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗
Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technology stocks toward their worst week since April. 
Via Benzinga
Topics Artificial Intelligence
News headline image
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
AbCellera's Q3 2025 results show revenue beat estimates, but the net loss widened, causing a negative after-hours stock reaction. 
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus ↗
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
News headline image
Why Did AbCellera's Stock Jump Over 7% After Hours? ↗
AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performance expected in Q3 earnings. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today ↗
Via The Motley Fool
News headline image
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
News headline image
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
News headline image
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
News headline image
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday ↗
A week ago it was suggested that the AI/semiconductor stocks sector was oversold. The decline bottomed on Wednesday and by the close of business this past Friday the sector had rebounded nicely almost... 
Via Talk Markets
News headline image
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
News headline image
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD ↗
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.